18 completed, 10 active not recruiting, 7 recruiting, 2 terminated. 41 Phase 2, 14 Phase 1.
Follow Refractory Non-Hodgkin Lymphoma: new trials by email Literature Review of Refractory Non-Hodgkin Lymphoma trials Research Report on Refractory Non-Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Homoharringtonine, BCL-2 inhibitor, CD20 Antibody - Diffuse Large B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 62 | 2025-09-08 | 2025-09-08 |
| A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL ATRA, Pembrolizumab - Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 2 | Recruiting | Rita Assi | 24 | 2024-11-18 | 2026-02-10 |
| Emapalumab Prevention of CAR-T Cell Associated Toxicities Emapalumab, Cyclophosphamide, Fludarabine Phosphate - Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 2 | Recruiting | Marcela V. Maus, M.D.,Ph.D. | 28 | 2024-09-18 | 2026-10-06 |
| T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) EB103 - B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins | Phase 1 / Phase 2 | Recruiting | Estrella Immunopharma, Inc. | 27 | 2024-06-01 | 2026-10-01 |
| IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers IDP-023, Rituximab, Daratumumab - NHL, Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Indapta Therapeutics, INC. | 128 | 2023-10-25 | 2025-06-03 |
| Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma Rondecabtagene autoleucel (ronde-cel), Fludarabine, Cyclophosphamide - Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Lyell Immunopharma, Inc. | 270 | 2023-05-09 | 2026-08-25 |
| CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). Mosunetuzumab, Polatuzumab, CAR-T Cell Therapy - Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma | Phase 2 | Recruiting | Lazaros Lekakis | 22 | 2022-12-14 | 2025-12-31 |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint - Colorectal Carcinoma, Endometrial Carcinoma | Phase 1 / Phase 2 | Recruiting | Children's Oncology Group | 147 | 2021-11-08 | 2026-08-25 |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1 | 2021-05-03 | 2026-10-09 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Tipifarnib - Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2020-10-13 | 2026-10-16 |
| A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity Anakinra, Axicabtagene Ciloleucel - Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 2 | Completed | Marcela V. Maus, M.D.,Ph.D. | 15 | 2020-10-01 | 2025-11-25 |
| A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma CD19/22 CART, Tislelizumab - Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 2 | Completed | The First Affiliated Hospital of Soochow University | 18 | 2020-08-01 | 2026-06-02 |
| Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) Ivosidenib - Recurrent Ependymoma, Recurrent Ewing Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 3 | 2020-07-20 | 2026-07-01 |
| Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies Nivolumab - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | University of Washington | 20 | 2020-06-05 | 2026-06-26 |
| Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine - CD19 Positive, CD22 Positive | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-05-15 | 2023-08-21 | |
| 9-ING-41 in Patients With Advanced Cancers 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin. - Cancer, Pancreatic Cancer | Phase 2 | Active not recruiting | Actuate Therapeutics Inc. | 350 | 2019-01-04 | 2026-04-03 |
| Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma azacitidine plus R-GDP - Diffuse Large B Cell Lymphoma, Relapsed Non Hodgkin Lymphoma | Phase 2 | Unknown | Seoul National University Hospital | 27 | 2018-12-01 | 2018-10-25 |
| MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin Rituximab, Fludarabine, Cyclophosphamide - Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Unknown | GC Cell Corporation | 9 | 2018-11-28 | 2020-07-28 |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Pharmacokinetic Study, Ulixertinib - Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-11-14 | 2026-09-21 |
| Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma Carmustine, Cytarabine, Etoposide - Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 19 | 2018-09-10 | 2025-05-14 |
Showing 20 of 41. Sign in to see all of them.
Lymphoma, Non-Hodgkin (41) · Neuroblastoma (16) · Glioma (14) · Hepatoblastoma (14) · Neuroectodermal Tumors, Primitive, Peripheral (14) · Osteosarcoma (14) · Wilms Tumor (14) · Ependymoma (13) · Histiocytosis, Langerhans-Cell (13) · Rhabdoid Tumor (13) · Rhabdomyosarcoma (13) · Sarcoma (13) · Medulloblastoma (12) · Sarcoma, Ewing (10) · Central Nervous System Neoplasms (9)
Hemic and Lymphatic Diseases (41) · Immunoproliferative Disorders (41) · Lymphatic Diseases (41) · Lymphoproliferative Disorders (41) · Neoplasms by Histologic Type (41) · Immune System Diseases (40) · Neoplasms (40) · Lymphoma (38) · Neoplasms by Site (19) · Neoplasms, Germ Cell and Embryonal (17) · Neoplasms, Glandular and Epithelial (17) · Neoplasms, Nerve Tissue (17) · Neoplasms, Neuroepithelial (17) · Neuroectodermal Tumors (17) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (16)
Cyclophosphamide (8) · Phantoms, Imaging (7) · X-Rays (7) · Magnetic Resonance Spectroscopy (6) · Specimen Handling (6) · Nuclear Medicine Department, Hospital (5) · Rituximab (5) · fludarabine phosphate (5) · Biopsy (4) · Cytarabine (4) · fludarabine (4) · Carmustine (3) · Dexamethasone (3) · Etoposide (3) · Melphalan (3)
National Cancer Institute (NCI) (16) · Fred Hutchinson Cancer Center (3) · M.D. Anderson Cancer Center (3) · Marcela V. Maus, M.D.,Ph.D. (2) · The First Affiliated Hospital of Soochow University (2) · University of Washington (2) · Actuate Therapeutics Inc. (1) · Children's Oncology Group (1) · Estrella Immunopharma, Inc. (1) · First Affiliated Hospital of Zhejiang University (1) · GC Cell Corporation (1) · Indapta Therapeutics, INC. (1) · La Raza Medical Center (1) · Lazaros Lekakis (1) · Lyell Immunopharma, Inc. (1)
United States (35) · Puerto Rico (14) · Australia (5) · Canada (4) · China (3) · South Korea (2) · Belgium (1) · France (1) · Germany (1) · Mexico (1) · Netherlands (1) · Portugal (1) · Spain (1)
AeRang Kim (1) · Ajay K. Gopal (1) · Alice Lee (1) · Andrea T Franson (1) · Carl E Allen (1) · Chelsea C Pinnix (1) · Christine A Pratilas (1) · Crystal L Mackall (1) · David Maloney (1) · Depei Wu, M.D. (1) · Donald W Parsons (1) · Elizabeth D Alva (1) · Jin S Im (1) · Jordan Gauthier (1)
PMID 31401903, PMID 24327518, PMID 27111235, PMID 27424289, PMID 28053024, PMID 28672195, PMID 29038338, PMID 29383130, PMID 29846250, PMID 30405781, PMID 30728140, PMID 30729531, PMID 30782611, PMID 30975030, PMID 31101621, PMID 31219975, PMID 31335321, PMID 31533931, PMID 31648294, PMID 31831767, PMID 31882719, PMID 31894292, PMID 32192573, PMID 32499241, PMID 32967009, PMID 33591402, PMID 34113569, PMID 34486544, PMID 34515338, PMID 34666344, PMID 35353553, PMID 35363510, PMID 35432352, PMID 35815408, PMID 36131934, PMID 37774014, PMID 38815151, PMID 38873934, PMID 38935895, PMID 39298716, PMID 39333103, PMID 39928957, PMID 40656663, PMID 41166674, PMID 41981308, PMID 42389828, PMID 42686334, PMID 42853672, PMID 42867148
U10CA180886 (14), P30CA015704 (2), P30CA016672 (1), P50CA107399 (1), R01CA136551 (1), U10CA021115 (1), U10CA180820 (1), UM1CA081457 (1), UM1CA097452 (1), UM1CA228823 (1)